Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer.
Cato L, Neeb A, Sharp A, Buzón V, Ficarro SB, Yang L, Muhle-Goll C, Kuznik NC, Riisnaes R, Nava Rodrigues D, Armant O, Gourain V, Adelmant G, Ntim EA, Westerling T, Dolling D, Rescigno P, Figueiredo I, Fauser F, Wu J, Rottenberg JT, Shatkina L, Ester C, Luy B, Puchta H, Troppmair J, Jung N, Bräse S, Strähle U, Marto JA, Nienhaus GU, Al-Lazikani B, Salvatella X, de Bono JS, Cato AC, Brown M.
Cato L, et al. Among authors: buzon v.
Elife. 2017 Aug 10;6:e27159. doi: 10.7554/eLife.27159.
Elife. 2017.
PMID: 28826504
Free PMC article.